Abstract: A vehicle system and method for remote start operation in the vehicle system are provided. The method includes responsive to receiving a remote start request and while the vehicle is stationary, automatically engaging a wheel-arresting device coupled to a wheel in the vehicle. The method also includes when an electronically actuated clutch is automatically disengaged and subsequent to the automatic engagement of the wheel-arresting device, implementing remote start operation in an engine, where the wheel-arresting device is distinct from a secondary vehicle brake.

Abstract: A vehicle includes an powerplant, a manual transmission, and a clutch. A vehicle controller is programmed to automatically control operation of the clutch allowing the driver to shift gears by just operating the gear shifter. The vehicle also includes an input allowing the driver to override the controller and operate the clutch. The input is located on the gear shifter and is in electric communication with the controller. The controller is programmed to, inter alia, command the clutch to reduce clutch capacity responsive to receiving a signal from the sensor indicating grasping of the shifter.

Abstract: A vehicle system and method for remote start operation in the vehicle system are provided. The method includes responsive to receiving a remote start request and while the vehicle is stationary, automatically engaging a wheel-arresting device coupled to a wheel in the vehicle. The method also includes when an electronically actuated clutch is automatically disengaged and subsequent to the automatic engagement of the wheel-arresting device, implementing remote start operation in an engine, where the wheel-arresting device is distinct from a secondary vehicle brake.

Abstract: A vehicle includes an powerplant, a manual transmission, and a clutch. A vehicle controller is programmed to automatically control operation of the clutch allowing the driver to shift gears by just operating the gear shifter. The vehicle also includes an input allowing the driver to override the controller and operate the clutch. The input is located on the gear shifter and is in electric communication with the controller. The controller is programmed to, inter alia, command the clutch to reduce clutch capacity responsive to receiving a signal from the sensor indicating grasping of the shifter.

Abstract: The present invention provides Pyrazolopyrimidine Compounds of Formula (I): wherein L, T, Z, U, V, W, R3, R6, R7, R8, and m are as defined herein, and pharmaceutically acceptable salts of such Pyrazolopyrimidine Compounds. The Pyrazolopyrimidine Compounds are useful in the treatment of cancer and other diseases or disorders wherein mTOR is deregulated.

Abstract: The present invention provides Pyrazolopyrimidine Compounds of Formula (I): wherein L, T, Z, U, V, W, R3, R6, R7, R8, and m are as defined herein, and pharmaceutically acceptable salts of such Pyrazolopyrimidine Compounds. The Pyrazolopyrimidine Compounds are useful in the treatment of cancer and other diseases or disorders wherein mTOR is deregulated.

Abstract: Disclosed are compounds of the formula (I) wherein X is N or CH, and Y is N or CR5. Also disclosed are methods of treating JNK and ERK mediated diseases using the compounds of formula 1.0.

Abstract: An apparatus and method are provided for steaming and blending food products such as baby food. The apparatus includes a base including a steam chamber and a drive shaft. A container assembly can be mounted to the base in an inverted position for steaming the food and in an upright position for blending the food. The apparatus may further include a steam cooker, baby bottle sterilizing unit and a bottle warmer.

Abstract: Disclosed are compounds of the formula (I) wherein X is N or CH, and Y is N or CR5. Also disclosed are methods of treating JNK and ERK mediated diseases using the compounds of formula 1.0.

Abstract: A portable toilet is provided comprising a bowl provided with an outlet and at least one spout. A flush tank is adapted to store a fluid, wherein the flush tank is adapted to be pressurized. A manually-actuated pump is in sealed communication with the flush tank, wherein the pump is adapted to cause the flush tank to become pressurized. A pressure relief valve adapted to release pressure from the flush tank. A manually-actuated flush valve is in sealed communication with the flush tank and is normally biased to a closed position. The flush valve includes a fluid outlet connected to the at least one spout and a fluid inlet. A flush valve actuator is disposed outside of the flush tank and is adapted to actuate the flush valve, wherein actuation of the flush valve actuator causes the flush valve to open to permit pressurized fluid contained within the flush tank to be delivered through the at least one spout.

Abstract: In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyrazine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

Abstract: In its many embodiments, the present invention provides a class of pyrazolo [1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases (CDKs), methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

Abstract: Quinoline-based inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.

Abstract: In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or Aurora kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or Aurora kinases using such compounds or pharmaceutical compositions.

Abstract: Inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.

Abstract: The present invention provides compounds of formula I wherein X, Y, R1-R7 are as defined herein. Compositions containing these compounds, and methods for inhibiting HCV RNA-dependent RNA polymerase and treating hepatitis C and related disorders using these compounds and compositions are also provided.

Abstract: In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or Aurora kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or Aurora kinases using such compounds or pharmaceutical compositions.

Abstract: Quinoline-based inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.

Abstract: The invention relates to the inhibition of hepatitis C virus (HCV) replication. In particular, embodiments of the invention provide compounds and methods for inhibiting HCV RNA-dependent RNA polymerase enzymatic activity. The invention also provides compositions and methods for the prophylaxis and treatment of HCV infection.

Abstract: The present invention provides compounds of formula I wherein X and R1–R7 are as defined herein.